Trupanion Reports Second Quarter 2023 Results


SEATTLE, Wash., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), the leading provider of medical insurance for cats and dogs, today announced financial results for the second quarter ended June 30, 2023.

“In the second quarter, we saw early signs of margin expansion, while exercising discipline in our capital deployment. As a result, we delivered sequential improvement in free cash flow, marking progress towards our goal of being free cash flow positive in the fourth quarter of 2023,” said Darryl Rawlings, Trupanion’s founder, CEO and Chair of the Board.


Fig 1


Second Quarter 2023 Financial and Business Highlights

  • Total revenue was $270.6 million, an increase of 23% compared to the second quarter of 2022.
  • Total enrolled pets (including pets from our other business segment) was 1,679,659 at June 30, 2023, an increase of 25% over the second quarter of 2022.
  • Subscription business revenue was $173.3 million, an increase of 19% compared to the second quarter of 2022 (20% on a constant currency basis).
  • Subscription enrolled pets was 943,958 at June 30, 2023, an increase of 23% over the second quarter of 2022.
  • Net loss was $(13.7) million, or $(0.33) per basic and diluted share, compared to net loss of $(13.6) million, or $(0.33) per basic and diluted share, in the second quarter of 2022.
  • Adjusted EBITDA was $(3.2) million, compared to adjusted EBITDA of $(1.7) million in the second quarter of 2022.
  • Operating cash flow was $(3.4) million and free cash flow was $(8.1) million in the second quarter of 2023. This compared to operating cash flow of $(3.1) million and free cash flow of $(7.1) million in the second quarter of 2022. Sequentially, free cash flow improved $3.9 million from the first quarter of 2023.

First Half 2023 Financial and Business Highlights

  • Total revenue was $526.9 million, an increase of 24% compared to the first half of 2022.
  • Subscription business revenue was $338.5 million, an increase of 18% compared to the first half of 2022 (20% on a constant currency basis).
  • Net loss was $(38.5) million, or $(0.93) per basic and diluted share, compared to net loss of $(22.5) million, or $(0.55) per basic and diluted share, in the first half of 2022. Net loss for the six months ended June 30, 2023 included $4.2 million, or $0.10 per basic and diluted share, of non-recurring expenses
  • Adjusted EBITDA was $(8.1) million, compared to adjusted EBITDA of $(0.5) million in the first half of 2022.
  • Operating cash flow was $(10.3) million and free cash flow was $(20.2) million in the first half of 2023. This compared to operating cash flow of $(6.7) million and free cash flow of $(14.2) million in the first half of 2022.
  • At June 30th, 2023, the Company held $236.1 million in cash and short-term investments. The Company maintained $213.1 million of capital surplus at its insurance subsidiaries. This was $57.3 million more than the estimated risk-based capital requirement of $155.8 million. In addition to these insurance entities, the Company held $25.4 million in cash & short-term investments at the end of the quarter, with additional $40 million available under its credit facility.

Conference Call
Trupanion’s management will host a conference call today to review its second quarter 2023 results. The call is scheduled to begin shortly after 1:30 p.m. PT/ 4:30 p.m. ET. A live webcast will be accessible through the Investor Relations section of Trupanion’s website at https://investors.trupanion.com/ and will be archived online for 3 months upon completion of the conference call. Participants can access the conference call by dialing 1-877-300-8521 (United States) or 1-412-317-6026 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 10180014.

About Trupanion
Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada, Europe, Puerto Rico and Australia with over 900,000 pets enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance with unlimited payouts for the life of their pets. With its patented process, Trupanion is the only North American provider with the technology to pay veterinarians directly in seconds at the time of checkout. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Omega General Insurance Company. Trupanion Australia is a partnership between Trupanion and Hollard Insurance Company. For more information, please visit trupanion.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to, among other things, expectations, plans, prospects and financial results for Trupanion, including, but not limited to, its expectations regarding its ability to continue to grow its enrollments and revenue, and otherwise execute its business plan. These forward-looking statements are based upon the current expectations and beliefs of Trupanion’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements made in this press release are based on information available to Trupanion as of the date hereof, and Trupanion has no obligation to update these forward-looking statements.

In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods; the ability to keep growing our membership base and revenue; the accuracy of assumptions used in determining appropriate member acquisition expenditures; the severity and frequency of claims; the ability to maintain high retention rates; the accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency; actual claims expense exceeding estimates; regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense; the effectiveness and statutory or regulatory compliance of our Territory Partner model and of our Territory Partners, veterinarians and other third parties in recommending medical plan subscriptions to potential members; the ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals; compliance by us and those referring us members with laws and regulations that apply to our business, including the sale of a pet medical plan; the ability to maintain the security of our data; fluctuations in the Canadian currency exchange rate; the ability to protect our proprietary and member information; the ability to maintain our culture and team; the ability to maintain the requisite amount of risk-based capital; our ability to implement and maintain effective controls, including over financial reporting; the ability to protect and enforce Trupanion’s intellectual property rights; the ability to successfully implement our alliance with Aflac; the ability to continue key contractual relationships with third parties; third-party claims including litigation and regulatory actions; the ability to recognize benefits from investments in new solutions and enhancements to Trupanion’s technology platform and website; and our ability to retain key personnel.

For a detailed discussion of these and other cautionary statements, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion’s Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequently filed reports on Forms 10-Q, 10-K and 8-K. All documents are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system at https://www.sec.gov or the Investor Relations section of Trupanion’s website at https://investors.trupanion.com.

Non-GAAP Financial Measures
Trupanion’s stated results may include certain non-GAAP financial measures. These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in its industry as other companies in its industry may calculate or use non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Trupanion’s reported financial results. The presentation and utilization of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Trupanion urges its investors to review the reconciliation of its non-GAAP financial measures to the most directly comparable GAAP financial measures in its consolidated financial statements, and not to rely on any single financial or operating measure to evaluate its business. These reconciliations are included below and on Trupanion’s Investor Relations website.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, Trupanion believes that providing various non-GAAP financial measures that exclude stock-based compensation expense and depreciation and amortization expense allows for more meaningful comparisons between its operating results from period to period. Trupanion offsets new pet acquisition expense with sign-up fee revenue in the calculation of net acquisition cost because it collects sign-up fee revenue from new members at the time of enrollment and considers it to be an offset to a portion of Trupanion’s new pet acquisition expense. Trupanion believes this allows it to calculate and present financial measures in a consistent manner across periods. Trupanion’s management believes that the non-GAAP financial measures and the related financial measures derived from them are important tools for financial and operational decision-making and for evaluating operating results over different periods of time.

 
Trupanion, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share data)
 
 Three Months Ended June 30, Six Months Ended June 30,
  2023   2022   2023   2022 
 (unaudited)
Revenue:       
Subscription business$173,253  $145,808  $338,463  $285,647 
Other business 97,313   73,603   188,432   139,763 
Total revenue 270,566   219,411   526,895   425,410 
Cost of revenue:       
Subscription business(1) 151,520   122,440   297,611   237,703 
Other business 89,673   68,388   173,565   129,230 
Total cost of revenue(2) 241,193   190,828   471,176   366,933 
Operating expenses:       
Technology and development(1) 5,232   6,396   10,132   11,625 
General and administrative(1) 13,136   9,227   34,153   18,593 
New pet acquisition expense(1) 20,769   22,982   42,411   44,609 
Depreciation and amortization 3,253   2,707   6,455   5,424 
Total operating expenses 42,390   41,312   93,151   80,251 
Gain (loss) from investment in joint venture (73)  (42)  (144)  (111)
Operating loss (13,090)  (12,771)  (37,576)  (21,885)
Interest expense 2,940   1,193   5,327   1,272 
Other income, net (2,078)  (365)  (3,980)  (679)
Loss before income taxes (13,952)  (13,599)  (38,923)  (22,478)
Income tax expense (benefit) (238)  19   (429)  (5)
Net loss$(13,714) $(13,618) $(38,494) $(22,473)
        
Net loss per share:       
Basic and diluted$(0.33) $(0.33) $(0.93) $(0.55)
Weighted average shares of common stock outstanding:       
Basic and diluted 41,383,411   40,738,738   41,246,411   40,660,797 
                
(1)Includes stock-based compensation expense as follows:Three Months Ended June 30,
  Six Months Ended June 30,
  2023   2022   2023   2022 
Cost of revenue$1,307  $1,830  $2,625  $3,666 
Technology and development 627   1,101   1,335   2,009 
General and administrative 2,948   3,066   11,167   5,489 
New pet acquisition expense 1,755   2,637   3,841   5,019 
Total stock-based compensation expense$6,637  $8,634  $18,968  $16,183 
        
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:
 Three Months Ended June 30, Six Months Ended June 30,
  2023   2022   2023   2022 
Veterinary invoice expense$206,738  $157,616  $400,875  $302,542 
Other cost of revenue 34,455   33,212   70,301   64,391 
Total cost of revenue$241,193  $190,828  $471,176  $366,933 


 
Trupanion, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
 
 June 30, 2023 December 31, 2022
 (unaudited)  
Assets   
Current assets:   
Cash and cash equivalents$118,417  $65,605 
Short-term investments 117,648   156,804 
Accounts and other receivables, net of allowance for doubtful accounts of $701 at June 30, 2023 and $540 at December 31, 2022 265,648   232,439 
Prepaid expenses and other assets 18,882   14,248 
Total current assets 520,595   469,096 
Restricted cash 18,131   19,032 
Long-term investments 9,818   7,841 
Property, equipment and internal-use software, net 97,984   90,701 
Intangible assets, net 21,633   24,031 
Other long-term assets 18,153   18,943 
Goodwill 43,877   41,983 
Total assets$730,191  $671,627 
Liabilities and stockholders’ equity   
Current liabilities:   
Accounts payable$6,918  $9,471 
Accrued liabilities and other current liabilities 29,893   32,616 
Reserve for veterinary invoices 56,202   43,734 
Deferred revenue 236,545   202,692 
Long-term debt - current portion 1,100   1,103 
Total current liabilities 330,658   289,616 
Long-term debt 102,934   68,354 
Deferred tax liabilities 2,940   3,392 
Other liabilities 4,901   4,968 
Total liabilities 441,433   366,330 
Stockholders’ equity:   
Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 42,498,924 and 41,470,738 issued and outstanding at June 30, 2023; 42,041,344 and 41,013,158 shares issued and outstanding at December 31, 2022     
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding     
Additional paid-in capital 519,450   499,694 
Accumulated other comprehensive loss (4,102)  (6,301)
Accumulated deficit (210,056)  (171,562)
Treasury stock, at cost: 1,028,186 shares at June 30, 2023 and December 31, 2022 (16,534)  (16,534)
Total stockholders’ equity 288,758   305,297 
Total liabilities and stockholders’ equity$730,191  $671,627 


 
Trupanion, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
 
 Three Months Ended June 30, Six Months Ended June 30,
  2023   2022   2023   2022 
 (unaudited)
Operating activities       
Net loss$(13,714) $(13,618) $(38,494) $(22,473)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:       
Depreciation and amortization 3,253   2,707   6,455   5,424 
Stock-based compensation expense 6,637   8,634   18,968   16,183 
Other, net (188)  5   (585)  (74)
Changes in operating assets and liabilities:       
Accounts and other receivables (17,337)  (15,312)  (33,184)  (39,127)
Prepaid expenses and other assets 552   (761)  (3,213)  (2,821)
Accounts payable, accrued liabilities, and other liabilities (1,316)  2,509   (6,464)  703 
Reserve for veterinary invoices 7,833   (1,785)  12,439   (2,998)
Deferred revenue 10,875   14,491   33,811   38,463 
Net cash provided by (used in) operating activities (3,405)  (3,130)  (10,267)  (6,720)
Investing activities       
Purchases of investment securities (45,136)  (24,476)  (79,931)  (47,368)
Maturities and sales of investment securities 43,859   19,013   117,652   31,212 
Purchases of property, equipment, and internal-use software (4,735)  (3,926)  (9,919)  (7,479)
Other 483   (1,497)  583   (1,502)
Net cash provided by (used in) investing activities (5,529)  (10,886)  28,385   (25,137)
Financing activities       
Proceeds from debt financing, net of financing fees    (32)  35,130   54,431 
Repayment of debt financing (435)  (150)  (1,042)  (150)
Repurchases of common stock    (5,751)     (5,751)
Proceeds from exercise of stock options 513   571   653   1,171 
Shares withheld to satisfy tax withholding (171)  (632)  (1,024)  (2,930)
Net cash provided by (used in) financing activities (93)  (5,994)  33,717   46,771 
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net (184)  (835)  76   (696)
Net change in cash, cash equivalents, and restricted cash (9,211)  (20,845)  51,911   14,218 
Cash, cash equivalents, and restricted cash at beginning of period 145,759   135,932   84,637   100,869 
Cash, cash equivalents, and restricted cash at end of period$136,548  $115,087  $136,548  $115,087 


The following tables set forth our key operating metrics:

 
                
 Six Months Ended
June 30,
            
  2023   2022             
Total Business:               
Total pets enrolled (at period end) 1,679,659   1,348,145             
Subscription Business:               
Total subscription pets enrolled (at period end) 943,958   770,318             
Monthly average revenue per pet$64.00  $64.24             
Lifetime value of a pet, including fixed expenses$470  $713             
Average pet acquisition cost (PAC)$241  $305             
Average monthly retention 98.61%  98.74%            
                
                
 Three Months Ended
 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022 Sep. 30, 2022 Jun. 30, 2022 Mar. 31, 2022 Dec. 31, 2021 Sept. 30, 2021
Total Business:               
Total pets enrolled (at period end) 1,679,659   1,616,865   1,537,573   1,439,605   1,348,145   1,267,253   1,176,778   1,104,376 
Subscription Business:               
Total subscription pets enrolled (at period end) 943,958   906,369   869,862   808,077   770,318   736,691   704,333   676,463 
Monthly average revenue per pet$64.41  $63.58  $63.11  $63.80  $64.26  $64.21  $63.89  $63.60 
Lifetime value of a pet, including fixed expenses$470  $541  $641  $673  $713  $730  $717  $697 
Average pet acquisition cost (PAC)$236  $247  $283  $268  $309  $301  $306  $280 
Average monthly retention 98.61%  98.65%  98.69%  98.71%  98.74%  98.75%  98.74%  98.72%


Total pets enrolled and total subscription pets enrolled include pet enrollments in European markets, where policies are currently underwritten by third parties and Trupanion is acting as an insurance broker.  Per pet metrics, however, exclude these European policies, as their revenue is currently earned from commissions, as opposed to the gross underwriting premiums earned by the remainder of our subscription business.

 
The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands):
        
 Three Months Ended June 30, Six Months Ended June 30,
  2023   2022   2023   2022 
Net cash used in operating activities$(3,405) $(3,130) $(10,267) $(6,720)
Purchases of property, equipment, and internal-use software (4,735)  (3,926)  (9,919)  (7,479)
Free cash flow$(8,140) $(7,056) $(20,186) $(14,199)


The following tables reflect the reconciliation between GAAP and non-GAAP measures (in thousands except percentages):
 
  Three Months Ended June 30, Six Months Ended June 30,
   2023   2022   2023   2022 
Veterinary invoice expense $206,738  $157,616  $400,875  $302,542 
Less:        
Stock-based compensation expense1  (856)  (1,022)  (1,695)  (2,195)
Other business cost of paying veterinary invoices  (72,443)  (50,378)  (137,592)  (94,714)
Subscription cost of paying veterinary invoices (non-GAAP) $133,439  $106,216  $261,588  $205,633 
% of subscription revenue  77.0%  72.8%  77.3%  72.0%
         
Other cost of revenue $34,455  $33,212  $70,301  $64,391 
Less:        
Stock-based compensation expense1  (428)  (754)  (876)  (1,385)
Other business variable expenses  (17,230)  (18,010)  (35,973)  (34,516)
Subscription variable expenses (non-GAAP) $16,797  $14,448  $33,452  $28,490 
% of subscription revenue  9.7%  9.9%  9.9%  10.0%
         
Technology and development expense $5,232  $6,396  $10,132  $11,625 
General and administrative expense  13,136   9,227   34,153   18,593 
Less:        
Stock-based compensation expense1  (3,497)  (4,085)  (12,318)  (7,311)
Non-recurring transaction or restructuring expenses2  (65)     (4,167)   
Development expenses3  (925)  (2,012)  (1,823)  (3,270)
Fixed expenses (non-GAAP) $13,881  $9,526  $25,977  $19,637 
% of total revenue  5.1%  4.3%  4.9%  4.6%
         
New pet acquisition expense $20,769  $22,982  $42,411  $44,609 
Less:        
Stock-based compensation expense1  (1,722)  (2,601)  (3,754)  (4,929)
Other business pet acquisition expense  (62)  (186)  (113)  (295)
Subscription acquisition cost (non-GAAP) $18,985  $20,195  $38,544  $39,385 
% of subscription revenue  11.0%  13.9%  11.4%  13.8%
         
1Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.1 million and $0.3 million for the three and six months ended June 30, 2023, respectively.
2Consists of business acquisition transaction expenses, severance and legal costs due to certain executives' departures, and a $3.8 million non-recurring settlement of accounts receivable in the first quarter of 2023 related to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers.
3As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend.


The following tables reflect the reconciliation of new pet acquisition expense, previously called "sales and marketing", to acquisition cost and net acquisition cost (in thousands):
                
 Six Months Ended
June 30,
            
  2023   2022             
New pet acquisition expense$42,411  $44,609             
Excluding:               
Stock-based compensation expense (3,754)  (4,929)            
Acquisition cost 38,657   39,680             
Net of:               
Sign-up fee revenue (2,408)  (2,454)            
Other business segment pet acquisition expense (113)  (295)            
Pet acquisition expense for commission-based policies (1,815)               
Net acquisition cost$34,321  $36,931             
                
 Three Months Ended
 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022 Sep. 30, 2022 Jun. 30, 2022 Mar. 31, 2022 Dec. 31, 2021 Sept. 30, 2021
New pet acquisition expense$20,769  $21,642  $22,457  $22,434  $22,982  $21,627  $19,845  $19,708 
Excluding:               
Stock-based compensation expense (1,722)  (2,032)  (2,079)  (2,108)  (2,601)  (2,328)  (2,136)  (2,112)
Acquisition cost 19,047   19,610   20,378   20,326   20,381   19,299   17,709   17,596 
Net of:               
Sign-up fee revenue (1,189)  (1,219)  (1,191)  (1,339)  (1,252)  (1,202)  (1,162)  (1,268)
Other business segment pet acquisition expense (62)  (51)  (65)  (181)  (186)  (109)  (76)  (134)
Pet acquisition expense for commission-based policies (888)  (927)  (443)               
Net acquisition cost$16,908  $17,413  $18,679  $18,806  $18,943  $17,988  $16,471  $16,194 


The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands):
                
 Six Months Ended
June 30,
            
  2023   2022             
Net loss$(38,494) $(22,473)            
Excluding:               
Stock-based compensation expense 18,643   15,819             
Depreciation and amortization expense 6,455   5,424             
Interest income (3,780)  (394)            
Interest expense 5,327   1,272             
Other non-operating expenses    (1)            
Income tax benefit (429)  (5)            
Non-recurring transaction or restructuring expenses 4,167                
(Gain) loss from equity method investment    (131)            
Adjusted EBITDA$(8,111) $(489)            
                
 Three Months Ended
 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022 Sep. 30, 2022 Jun. 30, 2022 Mar. 31, 2022 Dec. 31, 2021 Sept. 30, 2021
Net loss$(13,714) $(24,780) $(9,285) $(12,914) $(13,618) $(8,855) $(7,042) $(6,819)
Excluding:               
Stock-based compensation expense 6,503   12,140   8,412   8,306   8,462   7,358   6,808   6,443 
Depreciation and amortization expense 3,253   3,202   2,897   2,600   2,707   2,717   2,770   2,944 
Interest income (2,051)  (1,729)  (1,614)  (1,018)  (297)  (97)  (80)  (85)
Interest expense 2,940   2,387   1,587   1,408   1,193   79   9    
Other non-operating expenses             (1)        (1)
Income tax expense (benefit) (238)  (191)  (15)  496   19   (24)  1,034   (312)
Non-recurring transaction or restructuring expenses 65   4,102   193   179             
(Gain) loss from equity method investment             (131)         
Adjusted EBITDA$(3,242) $(4,869) $2,175  $(943) $(1,666) $1,178  $3,499  $2,170 
 

Contacts:

Investors:
Laura Bainbridge
Senior Vice President, Corporate Communications
Investor.Relations@trupanion.com